title: Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.
abstract: This retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the specific aim to compare outcomes of patients between 60 and 65 years old (N = 493) with those older than 65 years (N = 107). Except for donor age, there were no significant differences between the groups regarding patients, diseases, and allo-HSCT characteristics. At time of RIC allo-HSCT, 276 patients (46%) were in complete remission. With a median follow-up of 22.8 and 23.7 months in the younger and the older groups, respectively, 2-year relapse, nonrelapse mortality, disease-free survival, and overall survival rates were similar in both groups (29.6% vs. 20.4%; 29.9% vs. 34.6%; 40.6% vs. 46.7%; 49.2% vs. 50.2%, respectively; P = NS for all comparisons). In a Cox multivariate analysis, after adjustment for disease and transplant factors, age per se was not an adverse factor for survival (relative risk = 1.08; 95% confidence interval, 0.81-1.44, P = .62). We conclude that in selected patients, RIC allo-HSCT could be offered to patients over 65 years old.
authors.affiliation: Centre Hospitalier et Universitaire de Nantes, Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie, Université de Nantes and INSERM CRNCA UMR 892, Nantes, France. patrice.chevallier@chu-nantes.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Chevallier
authors.forename: Richard M
authors.initials: RM
authors.lastname: Szydlo
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizi
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Madalina
authors.initials: M
authors.lastname: Uzunov
authors.forename: Nathalie
authors.initials: N
authors.lastname: Fegueux
authors.forename: François
authors.initials: F
authors.lastname: Guilhot
authors.forename: Simona
authors.initials: S
authors.lastname: Lapusan
authors.forename: Nicole
authors.initials: N
authors.lastname: Gratecos
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Cahn
authors.forename: Gerard
authors.initials: G
authors.lastname: Socié
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: Anne
authors.initials: A
authors.lastname: Huynh
authors.forename: Sylvie
authors.initials: S
authors.lastname: Francois
authors.forename: Jacques-Olivier
authors.initials: JO
authors.lastname: Bay
authors.forename: Sébastien
authors.initials: S
authors.lastname: Maury
authors.forename: Agnes
authors.initials: A
authors.lastname: Buzyn
authors.forename: Nathalie
authors.initials: N
authors.lastname: Contentin
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000367:Age Factors; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous